Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

BACKGROUND: Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Neurol
Main Authors: Ziemssen, Tjalf, Engelmann, Ulrich, Jahn, Sigbert, Leptich, Alexandra, Kern, Raimar, Hassoun, Lina, Thomas, Katja
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950609/
https://ncbi.nlm.nih.gov/pubmed/27430352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0629-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados